Compare OZ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | PRLD |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 218.0M |
| IPO Year | 2020 | 2020 |
| Metric | OZ | PRLD |
|---|---|---|
| Price | $50.18 | $4.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 9.2K | ★ 536.3K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | $9,187,000.00 | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 243.44 | 73.43 |
| 52 Week Low | $48.50 | $0.75 |
| 52 Week High | $69.00 | $5.54 |
| Indicator | OZ | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 54.28 |
| Support Level | $50.00 | $1.09 |
| Resistance Level | $57.63 | $5.54 |
| Average True Range (ATR) | 0.71 | 0.57 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 34.16 | 57.54 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.